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The potent vasoconstrictor endothelin is a 21 amino acid peptide whose principal physiological
function is to regulate vascular tone. The generation of endothelin is crucially dependent on the
local presence and activity of endothelin converting enzyme-1 (ECE-1) expressed on the surface
of vascular endothelial cells. In this study, we have shown in endothelial cells that the enzyme is
phosphorylated, and that phosphorylation is increased by phorbol ester stimulation of protein
kinase C (PKC). Furthermore, by monitoring speciﬁc ECE-1 activity on the surface of live cells,
we also show that following PKC activation, enzyme activity is signiﬁcantly increased at the cell
surface, where it is positioned to catalyse the generation of active endothelin. We believe this
novel ﬁnding is unprecedented for a peptide processing enzyme. Indeed, this new knowledge
regarding the control of endothelin production by regulating ECE-1 activity at the cell surface
opens up a new area of endothelin biology and will provide novel insights into the physiology
and pathophysiology of endothelin and endothelin-associated diseases. In addition, the
information generated in these studies may provide valuable new insights into potential extra-
and intracellular targets for the pharmacological and perhaps even therapeutic regulation of
endothelin production and thus vascular tone.
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INTRODUCTION
The endothelins (ET-1, ET-2 and ET-3) are a
family of three closely related 21 amino acid peptides
encoded by three distinct genes (Inoue et al., 1989).
Since their discovery (Yanagisawa et al., 1988), the
endothelins (ET’s) have attracted great scientiﬁc and
clinical interest, which largely reﬂects their extremely
potent and long-lasting vasoconstrictor eﬀects
(Sakurai and Goto, 1993), as well as their possible
role(s) in tumour growth (Patel and Schrey, 1996) and
endocrine function (Mansour et al., 1997). The vaso-
constrictor action of endothelin is mediated via the
ETA receptor located on the surface of vascular
smooth muscle cells (Arai et al., 1990) and although
the three peptides are expressed in many cell types, the
most abundant isoform, ET-1, is almost exclusively
expressed by vascular endothelial cells (Yanagisawa
et al., 1988). The endothelins, unlike many other
bioactive peptides, are stored as partially processed
inactive precursors (big ET’s) comprising 38–41 ami-
no acids. Big ET is then cleaved upon secretion to the
21 amino acid bioactive ET by a highly speciﬁc
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1993). Therefore, the generation of bioactive ET-1 is
critically dependent on the presence and activity of
ECE on the surface of the cell.
The endothelin-converting enzyme-1 (ECE-1), is
a highly glycosylated, type II membrane-associated
neutral metalloendopeptidase (Shimada et al., 1994)
and is highly speciﬁc, cleaving big ET between Trp
21
and Val/Ile
22. Cloning studies have identiﬁed four
ECE-1 isoforms (ECE-1a, ECE-1b, ECE-1c and
ECE-1d) (Shimada et al., 1995; Valdenaire et al.,
1999), all encoded by the same gene. Studies using
mRNA protection analysis suggest that the ECE-1c
isoform is dominant and is therefore the principal
physiological regulator of ET production by endo-
thelial cells (Takahashi et al., 1995; Schweizer et al.,
1997). These ECE isoforms only diﬀer in their
cytoplasmic N-terminal tail, their selective expres-
sion reﬂecting the use of alternate promoters. Al-
though all four isoforms have similar catalytic
properties, the subtle N-terminal variations appear
to play an important role in diﬀerential subcellular
traﬃcking (Schweizer et al., 1997; Jafri and Ergul,
2003)
A recent report by MacLeod et al. (2002) showed
that ECE-1b, 1c & 1d are constitutively phosphory-
lated at Ser
18 and Ser
20 (ECE-1c numbering; Fig. 1),
most likely catalysed by casein kinase I. ECE-1a,
which does not contain these residues, is not consti-
tutively phosphorylated. We have now extended these
studies to show that the endothelial isoform, ECE-1c,
is not only constitutively phosphorylated as previ-
ously reported, but that the level of phosphorylation
is markedly increased following protein kinase C
(PKC) activation by phorbol esters. Furthermore, we
show that following PKC activation, ECE-1c activity
at the external surface of the endothelial cell plasma
membrane is increased. These results perhaps suggest
a novel mechanism for the rapid traﬃcking to and/or
activation of a metallopeptidase at the cell surface,
thus providing a physiological means to facilitate the
increased production of endothelin, without the need
for de novo synthesis of its precursor.
MATERIAL AND METHODS
Antibody Production
Polyclonal antibodies were raised in rabbits against the syn-
thetic peptide, TYKRATLDEEDLC (conjugated to keyhole limpet
haemocyanin through the C-terminal cysteine residue), corre-
sponding to the amino acid stretch between residues 4 and 15 of the
ECE-1cN-terminalcytoplasmictail(Mimotopes,Clayton,Victoria,
Australia) using standard procedures (Cooper and Paterson, 1997).
Western analyses were performed using membranes prepared from
immortalized EA.hy926 cells as described below. Speciﬁcity was
determined by pre-absorption where the serum was incubated with
10 lg/ml of non-conjugated peptide.
Gel Electrophoresis and Western Blotting
Proteins were resolved by SDS-polyacrylamide gel electro-
phoresis (8 or 10% acrylamide) under reducing conditions.
Resolved proteins were transferred to PVDF membrane, blocked
overnight in 5% w/v dry milk, and incubated with anti-ECE anti-
serum (1:5000 in 5% milk) for 1 h. Proteins were detected using
horseradish peroxidase conjugated sheep anti-rabbit IgG (1:1000)
and enhanced chemiluminescence detection system (NEN
TM Life
Science).
Cell Culture
Immortalized EA.hy926 cells were grown to 80% conﬂuency
in either 12-well culture plates (for phosphorylation studies) or
96-well microtitre plates (for cell-based ECE activity assays), as
previously described (Norman et al., 2003).
Phosphorylation and Immunoprecipitation of ECE-1c
The procedure for phosphorylation and immunoprecipitation
of ECE-1 was essentially as described by Thomas et al. (1998) for
the angiotensin type 1 receptor. Brieﬂy, EA.hy926 cells were serum
starved for 16 h, prior to incubation with [
32P]Pi (200 lCi/ml; ICN)
in phosphate-free medium. In some instances, cells were stimulated
by phorbol 12-myristate 13-acetate (PMA) (2 lM, 10 min) at 37C,
and when required, the PKC inhibitor bisindolmaleimide (BIM)
(2 lM), the CKII inhibitor apigenin (80 lM), or PD98059, a MAP
Fig. 1. Putative phosphorylation sites in the cytoplasmic domains of the four ECE-1 isoforms. The putative phosphorylation site(s) of PKC
are marked by p, of MAP kinase by d and of casein kinase II by . The start of the transmembrane domain is represented by italic characters,
while the sequence used to raise antisera is underlined. Searches were performed using ANGIS and Swiss PROT data bases.
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to PMAstimulation.Cells werelysed in the presenceof phosphatase
and protease inhibitors as described (Thomas et al., 1998) and after
pre-clearing with Protein-A agarose, lysates were incubated over-
night (4C) with 20 ll of Protein A-agarose and 2 ll of anti-ECE-1
antiserum. Washed immuno-precipitates were resolved onto 8%
SDS-PAGE, and dried gels were exposed overnight against a Fuji-
type BAS-IIIs PhosphorImaging plate. The plates were subse-
quently read in a FUJIX Bio-imaging Analyser BAS 1000 and the
data analysed using MacBAS version 1.0 software. Quantitative
data derived from phosphorimage analysis were normalized relative
to unstimulated cells. Results were compared using a Student’s
t-test, and p values < 0.05 were considered signiﬁcant.
Cell-based Quenched Fluorescent Substrate Assay
EA.hy926 cells grown in 96-well microtiter plates were washed
with Opti-MEM (Invitrogen Australia, Mt. Waverley, Victoria),
before adding 180 ll fresh Opti-MEM with or without 10 lMo r
50 lM thiorphan (Auspep, Parkville, Victoria) to inhibit neutral
endopeptidase (NEP), or 10 lM phosphoramidon (Sigma) to
inhibit both NEP and ECE-1. Following pre-incubation at 37C
for 30 min, a bradykinin-based quenched ﬂuorescent substrate
(QFS), (7-methoxycoumarin-4-yl)acetyl-Arg-Pro-Pro-Gly-Phe-Ser-
Ala-Phe- Lys(2, 4-dinitrophenyl) (custom synthesized by Auspep;
Johnson and Ahn, 2000), was added to a ﬁnal concentration of
40 lM. Fluorescence generated by cleavage of the QFS was con-
tinuously monitored (kex = 320 nm, kem = 405 nm) in a FLUO-
Star Optima plate reader (BMG LabTech, Oﬀenburg, Germany)
maintained at 37C. Each group (control, 10 lM thiorphan, 50 lM
thiorphan, or phosphoramidon) consisted of 3 wells. In a second
experiment, cells were pre-incubated in 10 lM thiorphan prior to
addition of QFS. At 30 min following QFS addition, PMA (2 lM
ﬁnal concentration) or its vehicle (Opti-MEM) was added to each
well using the automated injector function of the plate reader (10 ll
volume/well); ﬂuorescence was monitored for a further 90 min.
Each group (vehicle or PMA injection) consisted of 9 wells.
RESULTS
Endothelial ECE-1 is Phosphorylated
The amino acid sequence of the N-terminal
cytoplasmic tail of ECE-1 contains PKC, CKII and
MAPK consensus phosphorylation motifs (Fig. 1),
suggesting that the enzyme may be a kinase substrate
in mammalian cells. To determine if ECE-1 could be
phosphorylated, anti-ECE-1 antibodies were gener-
ated and used to immunoprecipitate [
32P]-labelled
ECE-1 from endothelial cells. Western blotting of
membranes prepared from the cells demonstrated
recognition of ECE-1 by our antiserum, as an
approximately 120 kDa protein was detected in
endothelial cells (data not shown). This band was not
detected using pre-immune serum or ECE-1c antise-
rum pre-absorbed with the synthetic peptide (data
not shown). Our antiserum could also eﬀectively
immunoprecipitate ECE-1, and phosphorylated
ECE-1 protein was detected in endothelial cells
(Fig. 2A).
PKC Activation Increases ECE-1 Phosphorylation
In endothelial cells, the phosphorylation of ECE-1
was increased (50–100% above basal levels) when
cells were treated with the PKC activator, PMA
(Fig. 2). In contrast, di-butyryl cAMP did not inﬂu-
ence ECE-1 phosphorylation in the endothelial cells
(Fig. 2A, lane 3), consistent with the absence of
classical putative PKA phosphorylation sites in ECE-
1. As expected, inhibition of PKC with BIM blocked
the eﬀect of PMA treatment on ECE-1 phosphory-
lation (Fig. 2B); interestingly, basal phosphorylation
was also reduced, but not completely blocked, by
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Fig. 2. Phosphorylation of ECE-1. Panel A: Phosphorimage of
phosphorylated ECE-1. Cell lysates from EA.hy926 endothelial
cells incubated in [
32P]Pi were immunoprecipitated using anti-ECE-
1 antibody, and resolved by SDS-PAGE prior to detection of
radioactivity by phosphorimage analysis. Cells were either
unstimulated (lane 1), stimulated with 2 lM PMA (lane 2), or with
200 lM dibutyryl cAMP (lane 3). Panel B: Eﬀect of PMA and BIM
on ECE-1 phosphorylation. EA.hy926 cells were incubated with
[
32P]Pi in the presence or absence of 2 lM PMA (10 min) or 2 lM
BIM (30 min) or both prior to immunoprecipitation and phos-
phorimage analysis as described and shown in panel A. Results
were expressed as percentage change compared with the unstimu-
lated control for each experiment. Data are means±SEM from 11
experiments (PMA stimulation) and 5 experiments (BIM treat-
ment). *p<0.05 vs. basal; p<0.05 vs. PMA-treated.
PKC Regulates ECE Traﬃcking 293BIM, suggesting a partial involvement of PKC in
constitutive levels of ECE phosphorylation. Neither
the CKII inhibitor apigenin, nor the MAP kinase
inhibitor PD98059 signiﬁcantly reduced basal or
PMA-induced phosphorylation of ECE-1 (data not
shown).
Extracellular ECE-1 Catalytic Activity
The eﬃcient cleavage of a bradykinin-based ECE-1
quenched ﬂuorescent substrate by intact EA.hy926
endothelial cells was partially inhibited by the neutral
endopeptidase inhibitor thiorphan and completely
blocked by inhibition of both NEP and ECE-1 by
phosphoramidon (Fig. 3A). Addition of the phorbol
ester PMA resulted in an increase in the rate of QFS
cleavage relative to the vehicle control (Fig. 3B),
suggesting a greater ECE-like catalytic capacity at the
cell surface as a consequence of PMA addition.
DISCUSSION
The only diﬀerences between the four isoforms of
human ECE-1 lie in the short N-terminal cytoplasmic
tail region (Fig. 1); however, and importantly in the
context of the current study, it is these diﬀerences that
inﬂuence the subcellular distribution of ECE (Cailler
et al., 1999; Muller et al., 2003). Experiments using
site-directed mutagenesis (alanine scans through the
tails of the ECE isoforms) have shown that, as in the
case of some other traﬃcked membrane proteins such
as G-protein coupled receptors, di-leucine and/or
Leu-Val internalization/retention motifs are likely
involved in this traﬃcking event (Cailler et al., 1999).
Interestingly, the ECE inhibitor phosphoramidon has
been shown to actually induce the internalization of
ECE in a dose-dependent manner (Barnes et al.,
1996). Taken together, these ﬁndings provide evidence
for an active pathway(s) for transferring ECE to and
from the cell surface. Experimental evidence using
cell-impermeable inhibitors as well as the conversion
of exogenous big ET (Kwan et al., 1998; Loﬄer, 2000)
suggests that ECE action occurs primarily at the
endothelial cell surface and that a molecular mecha-
nism exists to regulate ECE traﬃcking within the
endothelial cell. Given that we have previously shown
that the angiotensin AT1 receptor is internalized fol-
lowing agonist activation, a process dependent on
speciﬁc phosphorylation events in the cytoplasmic tail
of the receptor (Kule et al., 2004), we tested the
hypothesis that ECE can be phosphorylated and that
phosphorylation may impact on ECE activity at the
cell surface. In this context, examination of the cyto-
plasmic tails of the ECE isoforms reveals a number of
putative kinase recognition sites (Fig. 1). Indeed, our
studies show that immunoreactive ECE-1 natively
expressed in endothelial cells (EA.hy926) is constitu-
tively phosphorylated (Fig. 2). In the same study we
have shown that stimulation of PKC by the phorbol
ester PMA increases the level of phosphorylation in
endothelial cells (Fig. 2). Furthermore, these increases
can be blocked by prior treatment with the PKC
inhibitor BIM (Fig. 2), but not by inhibitors of casein
kinase II or PKA (data not shown).
Given that ECE-1c expression has been reported
both within the cell and at the cell surface, we
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Fig. 3. Cleavage of ECE-1 quenched ﬂuorescent substrate (QFS)
by EAhy926 endothelial cells in culture. Panel A: Endothelial cells
grown in 96-well microtiter plates were incubated with an ECE-1
QFS in the absence or presence of the NEP inhibitor thiorphan (10
or 50 lM) or the NEP/ECE inhibitor phosphoramidon (10 lM)
within a thermostatted plate reader, and ﬂuorescence continuously
monitored. Shown are the results depicting the mean nmoles of
QFS cleaved (n = 3 per group, ±s.e.m.) for every ﬁfth ﬂuores-
cence determination. Panel B: Treatment with PMA increases
cell-surface ECE-1 activity. Cells grown in 96-well plates were pre-
incubated for 30 min with 10 lM thiorphan prior to addition of
ECE-1 QFS. After a further 30 min, 10 ll vehicle or PMA (40 lM
stock) was added to each well. Shown are the results depicting the
mean nmoles of QFS cleaved (n = 8 per group, ±s.e.m.) for every
ﬁfth ﬂuorescence determination.
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lowing PKC activation may serve as a signal for the
traﬃcking of ECE-1c in endothelial cells. As phos-
phorylation is known to regulate internalization of
other cell surface proteins, we embarked on a study
designed to identify any changes in endothelial ECE-1
activity at the cell surface following PKC activation.
We therefore examined the capacity of intact
EA.hy926 endothelial cells to hydrolyse the ECE
quenched ﬂuorescent substrate both in the absence
and presence of PMA. The addition of PMA signiﬁ-
cantly increased the rate of hydrolysis (Fig. 3b), sug-
gesting increased catalytic capacity at the cell surface
and consistent with migration of ECE to the cell
surface. However, deﬁnitive cell surface labeling
studies (beyond the scope of the current study) would
be needed to unequivocally diﬀerentiate whether it is
catalytic activation and/or selective traﬃcking to the
cell surface following PKC mediated phosphorylation
that leads to enhanced cell surface ECE activity.
CONCLUDING REMARKS
The results of the studies outlined above show for
the ﬁrst time that the phosphorylation of ECE is reg-
ulated and that following phosphorylation ECE cat-
alytic activity is increased at the cell surface where it
can catalyse the generation of active endothelin. This
novel ﬁnding is, we believe, unprecedented for a pep-
tide-processing enzyme. Knowledge about the control
of endothelin production by regulating ECE-1 distri-
bution opens up a new area of endothelin biology and
will provide novel insights into the physiology and
pathophysiology of endothelin and endothelin-
associated diseases. Finally, the information gener-
ated in these studies may also provide valuable new
information about potential extra- and intracellular
targets for the pharmacological and perhaps thera-
peutic regulation of endothelin production.
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